Regulatory circuits of T cell function in cancer

Nature Reviews Immunology

Volumn 16, Issue 10, 2016, Pages 599-611

  Speiser, Daniel E ^a,b   Ho, Ping Chih ^a   Verdeil, Grégory ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE 1; INDOLEAMINE 2,3 DIOXYGENASE; MONOCLONAL ANTIBODY; STAT3 PROTEIN; TRANSCRIPTION FACTOR;

ADIPOCYTE; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; BONE MARROW CELL; CANCER ASSOCIATED FIBROBLAST; CANCER INHIBITION; CANCER RESEARCH; CANCER THERAPY; CARCINOGENESIS; CD8+ T LYMPHOCYTE; CELL COMMUNICATION; CELL THERAPY; DNA MODIFICATION; ENDOTHELIUM CELL; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; IMMUNE SYSTEM; IMMUNOPATHOLOGY; LYMPHOCYTE FUNCTION; METABOLISM; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SUPPRESSOR CELL; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ANIMAL; ENERGY METABOLISM; IMMUNOLOGY; IMMUNOMODULATION; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; NEOPLASMS; PATHOLOGY; PROCEDURES; SIGNAL TRANSDUCTION; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; CELL COMMUNICATION; ENERGY METABOLISM; HUMANS; IMMUNOMODULATION; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; NEOPLASMS; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TUMOR MICROENVIRONMENT;

EID: 84982144414     PISSN: 14741733     EISSN: 14741741     Source Type: Journal    
DOI: 10.1038/nri.2016.80     Document Type: Review

References (163)

1. + T cell differentiation. Nat. Rev. Immunol. 12, 749-761 (2012).
2. Smyth, M. J., Dunn, G. P. & Schreiber, R. D. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv. Immunol. 90, 1-50 (2006).
3. + T-Cell responses to influenza infection. Front. Immunol. 7, 25 (2016).
4. Lee, P. P. et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med. 5, 677-685 (1999).
5. Ahmadzadeh, M. et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114, 1537-1544 (2009).
6. Zippelius, A. et al. Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res. 64, 2865-2873 (2004).
7. + T cells in metastases from melanoma patients. J. Clin. Invest. 121, 2350-2360 (2011).
8. Giordano, M. et al. Molecular profiling of CD8 T cells in autochthonous melanoma identifies Maf as driver of exhaustion. EMBO J. 34, 2042-2058 (2015).
9. Quail, D. F. & Joyce, J. A. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19, 1423-1437 (2013).
10. Turley, S. J., Cremasco, V. & Astarita, J. L. Immunological hallmarks of stromal cells in the tumour microenvironment. Nat. Rev. Immunol. 15, 669-682 (2015).
11. Nishikawa, H. & Sakaguchi, S. Regulatory T cells in cancer immunotherapy. Curr. Opin. Immunol. 27, 1-7 (2014).
12. reg-mediated immune homeostasis. Nature 498, 506-510 (2013).
13. Peggs, K. S., Quezada, S. A., Chambers, C. A., Korman, A. J. & Allison, J. P. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J. Exp. Med. 206, 1717-1725 (2009).
14. Quezada, S. A. et al. Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J. Exp. Med. 205, 2125-2138 (2008).
15. + regulatory T cells in gastric cancer. Int. J. Cancer 122, 2286-2293 (2008).
16. reg cells. Nature 475, 226-230 (2011).
17. Ho, P. C. et al. Immune-based antitumor effects of BRAF inhibitors rely on signaling by CD40L and IFNγ. Cancer Res. 74, 3205-3217 (2014).
18. Perrot, I. et al. Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage. J. Immunol. 178, 2763-2769 (2007).
19. Engelhardt, J. J. et al. Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells. Cancer Cell 21, 402-417 (2012).
20. Gabrilovich, D. I. & Nagaraj, S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9, 162-174 (2009).
21. Mantovani, A., Sozzani, S., Locati, M., Allavena, P. & Sica, A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 23, 549-555 (2002).
22. + T cells foster immune privilege by regulating IDO expression in tumor-associated macrophages. J. Immunol. 188, 1117-1124 (2012).
23. Ye, X. Z. et al. Tumor-associated microglia/macrophages enhance the invasion of glioma stem-like cells via TGF-β1 signaling pathway. J. Immunol. 189, 444-453 (2012).
24. Colegio, O. R. et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature 513, 559-563 (2014).
25. Imtiyaz, H. Z. et al. Hypoxia-inducible factor 2α regulates macrophage function in mouse models of acute and tumor inflammation. J. Clin. Invest. 120, 2699-2714 (2010).
26. Hanahan, D. & Coussens, L. M. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21, 309-322 (2012).
27. Vonderheide, R. H. & Glennie, M. J. Agonistic CD40 antibodies and cancer therapy. Clin. Cancer Res. 19, 1035-1043 (2013).
28. Pyonteck, S. M. et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat. Med. 19, 1264-1272 (2013).
29. Kalluri, R. & Zeisberg, M. Fibroblasts in cancer. Nat. Rev. Cancer 6, 392-401 (2006).
30. Marsh, T., Pietras, K. & McAllister, S. S. Fibroblasts as architects of cancer pathogenesis. Biochim. Biophys. Acta 1832, 1070-1078 (2013).
31. Ko, S. Y. et al. HOXA9 promotes ovarian cancer growth by stimulating cancer-associated fibroblasts. J. Clin. Invest. 122, 3603-3617 (2012).
32. Erez, N., Truitt, M., Olson, P., Arron, S. T. & Hanahan, D. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-κB-dependent manner. Cancer Cell 17, 135-147 (2010).
33. Dirat, B. et al. Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion. Cancer Res. 71, 2455-2465 (2011).
34. Nieman, K. M. et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat. Med. 17, 1498-1503 (2011).
35. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57-70 (2000).
36. Carlos, T. M. Leukocyte recruitment at sites of tumor: dissonant orchestration. J. Leukoc. Biol. 70, 171-184 (2001).
37. Piali, L., Fichtel, A., Terpe, H. J., Imhof, B. A. & Gisler, R. H. Endothelial vascular cell adhesion molecule 1 expression is suppressed by melanoma and carcinoma. J. Exp. Med. 181, 811-816 (1995).
38. Motz, G. T. et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat. Med. 20, 607-615 (2014).
39. Mulligan, J. K., Rosenzweig, S. A. & Young, M. R. Tumor secretion of VEGF induces endothelial cells to suppress T cell functions through the production of PGE2. J. Immunother. 33, 126-135 (2010).
40. Ghesquiere, B., Wong, B. W., Kuchnio, A. & Carmeliet, P. Metabolism of stromal and immune cells in health and disease. Nature 511, 167-176 (2014).
41. Card, C. M., Yu, S. S. & Swartz, M. A. Emerging roles of lymphatic endothelium in regulating adaptive immunity. J. Clin. Invest. 124, 943-952 (2014).
42. MacIver, N. J., Michalek, R. D. & Rathmell, J. C. Metabolic regulation of T lymphocytes. Annu. Rev. Immunol. 31, 259-283 (2013).
43. Ho, P. C. et al. Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses. Cell 162, 1217-1228 (2015).
44. Chang, C. H. et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162, 1229-1241 (2015).
45. Zhao, E. et al. Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction. Nat. Immunol. 17, 95-103 (2016).
46. Choi, Y. S., Eto, D., Yang, J. A., Lao, C. & Crotty, S. Cutting edge: STAT1 is required for IL-6-mediated Bcl6 induction for early follicular helper cell differentiation. J. Immunol. 190, 3049-3053 (2013).
47. Yan, Y. et al. IDO upregulates regulatory T cells via tryptophan catabolite and suppresses encephalitogenic T cell responses in experimental autoimmune encephalomyelitis. J. Immunol. 185, 5953-5961 (2010).
48. Gajewski, T. F. et al. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr. Opin. Immunol. 25, 268-276 (2013).
49. Rodriguez, P. C. et al. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res. 69, 1553-1560 (2009).
50. Tanaka, K. et al. Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment. J. Clin. Invest. 125, 1591-1602 (2015).
51. Fischer, K. et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood 109, 3812-3819 (2007).
52. Robey, I. F. et al. Bicarbonate increases tumor pH and inhibits spontaneous metastases. Cancer Res. 69, 2260-2268 (2009).
53. Estrella, V. et al. Acidity generated by the tumor microenvironment drives local invasion. Cancer Res. 73, 1524-1535 (2013).
54. H2-dominant BALB/c mice. J. Immunol. 170, 757-764 (2003).
55. Eruslanov, E., Daurkin, I., Ortiz, J., Vieweg, J. & Kusmartsev, S. Pivotal advance: tumor-mediated induction of myeloid-derived suppressor cells and M2-polarized macrophages by altering intracellular PGE2 catabolism in myeloid cells. J. Leukoc. Biol. 88, 839-848 (2010).
56. Chen, J. H. et al. Prostaglandin E2 and programmed cell death 1 signaling coordinately impair CTL function and survival during chronic viral infection. Nat. Med. 21, 327-334 (2015).
57. Kurtova, A. V. et al. Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance. Nature 517, 209-213 (2015).
58. Deaglio, S. et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med. 204, 1257-1265 (2007).
59. Gabrilovich, D. I., Ostrand-Rosenberg, S. & Bronte, V. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12, 253-268 (2012).
60. + T cell subsets. J. Immunol. 186, 3299-3303 (2011).
61. Restifo, N. P., Smyth, M. J. & Snyder, A. Acquired resistance to immunotherapy and future challenges. Nat. Rev. Cancer 16, 121-126 (2016).
62. Spranger, S., Bao, R. & Gajewski, T. F. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature 523, 231-235 (2015).
63. Khalili, J. S. et al. Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin. Cancer Res. 18, 5329-5340 (2012).
64. Peng, W. et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov. 6, 202-216 (2016).
65. H1-type chemokines shapes tumour immunity and immunotherapy. Nature 527, 249-253 (2015).
66. Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G. & Hacohen, N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160, 48-61 (2015).
67. 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J. Natl Cancer Inst. 88, 100-108 (1996).
68. Karre, K., Ljunggren, H. G., Piontek, G. & Kiessling, R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319, 675-678 (1986).
69. Raulet, D. H. Missing self recognition and self tolerance of natural killer (NK) cells. Semin. Immunol. 18, 145-150 (2006).
70. Bessoles, S. et al. Adaptations of natural killer cells to self-MHC class I. Front. Immunol. 5, 349 (2014).
71. Winograd, R. et al. Induction of T-cell immunity overcomes complete resistance to PD1 and CTLA4 blockade and improves survival in pancreatic carcinoma. Cancer Immunol. Res. 3, 399-411 (2015).
72. Green, M. R. et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 11 6, 3268-3277 (2010).
73. Kataoka, K. et al. Aberrant PDL1 expression through 3′-UTR disruption in multiple cancers. Nature 534, 402-406 (2016).
74. Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell 161, 1681-1696 (2015).
75. Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252-264 (2012).
76. Taube, J. M. et al. Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci. Transl Med. 4, 127ra37 (2012).
77. Ribas, A. Adaptive immune resistance: how cancer protects from immune attack. Cancer Discov. 5, 915-919 (2015).
78. Woo, S. R., Corrales, L. & Gajewski, T. F. Innate immune recognition of cancer. Annu. Rev. Immunol. 33, 445-474 (2015).
79. Yang, X. et al. Targeting the tumor microenvironment with interferon-β bridges innate and adaptive immune responses. Cancer Cell 25, 37-48 (2014).
80. Baitsch, L., Fuertes-Marraco, S. A., Legat, A., Meyer, C. & Speiser, D. E. The three main stumbling blocks for anticancer T cells. Trends Immunol. 33, 364-372 (2012).
81. Nguyen, L. T. & Ohashi, P. S. Clinical blockade of PD1 and LAG3 - potential mechanisms of action. Nat. Rev. Immunol. 15, 45-56 (2015).
82. + T cells. Sci. Transl Med. 5, 200ra116 (2013).
83. Mahoney, K. M. & Atkins, M. B. Prognostic and predictive markers for the new immunotherapies. Oncology 28 (Suppl. 3), 39-48 (2014).
84. Barber, D. L. et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439, 682-687 (2006).
85. Zajac, A. J. et al. Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 188, 2205-2213 (1998).
86. + T cell differentiation during viral infection. Immunity 27, 393-405 (2007).
87. Speiser, D. E. et al. T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion? Nat. Rev. Immunol. 14, 768-774 (2014).
88. Wherry, E. J. & Kurachi, M. Molecular and cellular insights into T cell exhaustion. Nat. Rev. Immunol. 15, 486-499 (2015).
89. + regulatory T cells controlled by the transcription factor EGR2. Proc. Natl Acad. Sci. USA 106, 13974-13979 (2009).
90. Schietinger, A., Delrow, J. J., Basom, R. S., Blattman, J. N. & Greenberg, P. D. Rescued tolerant CD8 T cells are preprogrammed to reestablish the tolerant state. Science 335, 723-727 (2012).
91. + T cell peripheral tolerance mechanisms. J. Immunol. 193, 3409-3416 (2014).
92. Thomas, D. A. & Massague, J. TGFβ directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8, 369-380 (2005).
93. Delisle, J. S. et al. The TGFβ-SMAD3 pathway inhibits CD28-dependent cell growth and proliferation of CD4 T cells. Genes Immun. 14, 115-126 (2013).
94. Stephen, T. L. et al. Transforming growth factor β-mediated suppression of antitumor T cells requires FOXP1 transcription factor expression. Immunity 41, 427-439 (2014).
95. + T cells shows that PD1 inhibits T cell function by upregulating BATF. Nat. Med. 16, 1147-1151 (2010).
96. Fuertes Marraco, S. A., Neubert, N. J., Verdeil, G. & Speiser, D. E. Inhibitory receptors beyond T cell exhaustion. Front. Immunol. 6, 310 (2015).
97. + T cells. J. Exp. Med. 212, 1125-1137 (2015).
98. Walker, L. S. & Sansom, D. M. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat. Rev. Immunol. 11, 852-863 (2011).
99. Kuo, C. T. & Leiden, J. M. Transcriptional regulation of T lymphocyte development and function. Annu. Rev. Immunol. 17, 149-187 (1999).
100. + T cells. Immunity 42, 265-278 (2015).
101. Xiao, G., Deng, A., Liu, H., Ge, G. & Liu, X. Activator protein 1 suppresses antitumor T-cell function via the induction of programmed death 1. Proc. Natl Acad. Sci. USA 109, 15419-15424 (2012).
102. Baitsch, L. et al. Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization. PLoS ONE 7, e30852 (2012).
103. Coornaert, B. et al. T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-κB inhibitor A20. Nat. Immunol. 9, 263-271 (2008).
104. Giordano, M. et al. The tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20) imposes a brake on antitumor activity of CD8 T cells. Proc. Natl Acad. Sci. USA 111, 11115-11120 (2014).
105. + T cell fate coupled by T-bet and eomesodermin. Nat. Immunol. 6, 1236-1244 (2005).
106. + T cells. Nat. Immunol. 15, 373-383 (2014).
107. Sekiya, T. et al. NR4A receptors are essential for thymic regulatory T cell development and immune homeostasis. Nat. Immunol. 14, 230-237 (2013).
108. Fassett, M. S., Jiang, W., D'Alise, A. M., Mathis, D. & Benoist, C. Nuclear receptor NR4A1 modulates both regulatory T-cell (Treg) differentiation and clonal deletion. Proc. Natl Acad. Sci. USA 109, 3891-3896 (2012).
109. H17 cell-mediated autoimmune inflammation via IL-21 signalling. PLoS ONE 8, e56595 (2013).
110. + T cell exhaustion during chronic viral infection. Immunity 31, 309-320 (2009).
111. Shaffer, A. L. et al. BLIMP1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity 17, 51-62 (2002).
112. Shaffer, A. L. et al. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity 13, 199-212 (2000).
113. Harker, J. A., Lewis, G. M., Mack, L. & Zuniga, E. I. Late interleukin-6 escalates T follicular helper cell responses and controls a chronic viral infection. Science 334, 825-829 (2011).
114. + T cells by inducing Blimp1. Nat. Commun. 5, 3770 (2014).
115. Gonin, J. et al. Expression of IL-27 by tumor cells in invasive cutaneous and metastatic melanomas. PLoS ONE 8, e75694 (2013).
116. Hisada, M. et al. Potent antitumor activity of interleukin-27. Cancer Res. 64, 1152-1156 (2004).
117. Oniki, S. et al. Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma. Cancer Res. 66, 6395-6404 (2006).
118. Yu, H., Kortylewski, M. & Pardoll, D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol. 7, 41-51 (2007).
119. Waugh, K. A., Leach, S. M. & Slansky, J. E. Targeting transcriptional regulators of CD8+ T cell dysfunction to boost anti-tumor immunity. Vaccines 3, 771-802 (2015).
120. Kujawski, M. et al. Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects. Cancer Res. 70, 9599-9610 (2010).
121. + T cells inhibits their tumor accumulation by downregulating CXCR3/CXCL10 axis. Cancer Immunol. Res. 3, 864-870 (2015).
122. Triplett, T. A. et al. STAT3 signaling is required for optimal regression of large established tumors in mice treated with anti-OX40 and TGFβ receptor blockade. Cancer Immunol. Res. 3, 526-535 (2015).
123. Siveen, K. S. et al. Targeting the STAT3 signaling pathway in cancer: role of synthetic and natural inhibitors. Biochim. Biophys. Acta 1845, 136-154 (2014).
124. Sznol, M. & Chen, L. Antagonist antibodies to PD1 and B7-H1 (PDL1) in the treatment of advanced human cancer. Clin. Cancer Res. 19, 1021-1034 (2013).
125. Schadendorf, D. et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J. Clin. Oncol. 33, 1889-1894 (2015).
126. Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521-2532 (2015).
127. Garon, E. B. et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372, 2018-2028 (2015).
128. Sanchez-Paulete, A. R. et al. Cancer immunotherapy with immunomodulatory anti-CD137 and anti-PD1 monoclonal antibodies requires BATF3-dependent dendritic cells. Cancer Discov. 6, 71-79 (2016).
129. Lesokhin, A. M., Callahan, M. K., Postow, M. A. & Wolchok, J. D. On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. Sci. Transl Med. 7, 280sr1 (2015).
130. Khalil, D. N., Smith, E. L., Brentjens, R. J. & Wolchok, J. D. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat. Rev. Clin. Oncol. 13, 273-290 (2016).
131. Joyce, J. A. & Fearon, D. T. T cell exclusion, immune privilege, and the tumor microenvironment. Science 348, 74-80 (2015).
132. Zhu, Y. et al. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 74, 5057-5069 (2014).
133. June, C. H., Riddell, S. R. & Schumacher, T. N. Adoptive cellular therapy: a race to the finish line. Sci. Transl Med. 7, 280ps7 (2015).
134. + T-cell adoptive immunotherapy for large established tumors in mice. Clin. Cancer Res. 17, 5343-5352 (2011).
135. Gattinoni, L. et al. A human memory T cell subset with stem cell-like properties. Nat. Med. 17, 1290-1297 (2011).
136. Klebanoff, C. A. et al. Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy. J. Clin. Invest. 126, 318-334 (2016).
137. + T cell memory and antitumor function. J. Clin. Invest. 123, 4479-4488 (2013).
138. Crompton, J. G. et al. AKT inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics. Cancer Res. 75, 296-305 (2015).
139. Sukumar, M. et al. Mitochondrial membrane potential identifies cells with enhanced stemness for cellular therapy. Cell. Metab. 23, 63-76 (2016).
140. + T cells lacking T-bet and eomesodermin. Science 321, 408-411 (2008).
141. + T cells that induce regression of autochthonous melanoma. Cancer Res. 72, 76-87 (2012).
142. Grange, M. et al. Active STAT5 regulates T-bet and eomesodermin expression in CD8 T cells and imprints a T-bet-dependent Tc1 program with repressed IL-6/ TGFβ1 signaling. J. Immunol. 191, 3712-3724 (2013).
143. Dow, L. E. et al. Inducible in vivo genome editing with CRISPR-Cas9. Nat. Biotechnol. 33, 390-394 (2015).
144. Pauken, K. E. & Wherry, E. J. SnapShot: T cell exhaustion. Cell 163, 1038-1038.e1 (2015).
145. Hugo, W. et al. Non-genomic and immune evolution of melanoma acquiring MAPKi resistance. Cell 162, 1271-1285 (2015).
146. Smyth, M. J., Ngiow, S. F., Ribas, A. & Teng, M. W. Combination cancer immunotherapies tailored to the tumour microenvironment. Nat. Rev. Clin. Oncol. 13, 143-158 (2016).
147. Fridman, W. H., Pages, F., Sautes-Fridman, C. & Galon, J. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 12, 298-306 (2012).
148. Michalek, R. D. et al. Estrogen-related receptor-α is a metabolic regulator of effector T-cell activation and differentiation. Proc. Natl Acad. Sci. USA 108, 18348-18353 (2011).
149. Wang, R. et al. The transcription factor MYC controls metabolic reprogramming upon T lymphocyte activation. Immunity 35, 871-882 (2011).
150. Sinclair, L. V. et al. Control of amino-acid transport by antigen receptors coordinates the metabolic reprogramming essential for T cell differentiation. Nat. Immunol. 14, 500-508 (2013).
151. + T cell memory development. Immunity 36, 68-78 (2012).
152. + T cells use cell-intrinsic lipolysis to support the metabolic programming necessary for development. Immunity 41, 75-88 (2014).
153. + T cell longevity. Cell 161, 750-761 (2015).
154. van der Windt, G. J. et al. CD8 memory T cells have a bioenergetic advantage that underlies their rapid recall ability. Proc. Natl Acad. Sci. USA 11 0, 14336-14341 (2013).
155. Blagih, J. et al. The energy sensor AMPK regulates T cell metabolic adaptation and effector responses in vivo. Immunity 42, 41-54 (2015).
156. Siska, P. J. & Rathmell, J. C. T cell metabolic fitness in antitumor immunity. Trends Immunol. 36, 257-264 (2015).
157. Chang, C. H. & Pearce, E. L. Emerging concepts of T cell metabolism as a target of immunotherapy. Nat. Immunol. 17, 364-368 (2016).
158. + T cell exhaustion versus memory. Immunity 37, 1130-1144 (2012).
159. Mueller, S. N., Gebhardt, T., Carbone, F. R. & Heath, W. R. Memory T cell subsets, migration patterns, and tissue residence. Annu. Rev. Immunol. 31, 137-161 (2013).
160. Park, C. O. & Kupper, T. S. The emerging role of resident memory T cells in protective immunity and inflammatory disease. Nat. Med. 21, 688-697 (2015).
161. Fan, X. & Rudensky, A. Y. Hallmarks of tissue-resident lymphocytes. Cell 164, 1198-1211 (2016).
162. Herbst, R. S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563-567 (2014).
163. Speiser, D. E. & Flatz, L. Cancer immunotherapy drives implementation science in oncology. Hum. Vaccin. Immunother. 10, 3107-3110 (2014).